



सत्यमेव जयते

Report of the Comptroller and Auditor General of India



Assessment of Assesseees in Pharmaceuticals Sector

Union Government
Department of Revenue - Direct Taxes
Report No. 5 of 2015

**Report of the
Comptroller and Auditor General of India
for the year ended March 2014**

**Performance Audit
on
Assessment of Assesseees in
Pharmaceuticals Sector**

**Union Government
Department of Revenue - Direct Taxes
Report No. 5 of 2015**

Laid on the table of Lok Sabha / Rajya Sabha on

Table of Contents

Contents		Pages
A.	Preface	i
B.	Executive Summary	iii-iv
C.	Summary of Recommendations	v-vii
D.	Chapter I: Introduction	1-5
	D.1 Introduction	1-2
	D.2 Why we chose the topic	2
	D.3 Organizational set up	2-3
	D.4 Legal provisions	3-4
	D.5 Audit objectives and Audit scope	4
E.	Chapter II: Systemic Issues and Internal Control	7-19
	E.1 Impact of revenue foregone to the pharmaceuticals sector	7-8
	E.2 Sector wise data in the ITD	8-9
	E.3 Allowance of R&D expenditure awaiting approval from DSIR	9-10
	E.4 Allowance of weighted deduction of R & D expenditure under Section 35(2AB)	10-13
	E.5 Deduction of TDS in respect of contract entered by assessee company with a manufacturing company for manufacture of products	14-15
	E.6 Allowance of excess deduction in respect of Partnership Firm	15-16
	E.7 Maintenance of data of brought forward loss or unabsorbed depreciation	16-18
	E.8 Mechanism for cross-verification of turnover declared in income tax return with the turnover declared in excise return	18
F.	Chapter III : Compliance Issues	20-49
	<i>Section A: Inadmissible expenses related to Pharmaceuticals Sector</i>	21-27
	F.1 Allowance of expenditure towards gifts, freebies etc. to Medical Professionals	21-24
	F.2 Break up of expenditure on freebies / gifts not taken from sales promotion expenses	24-25
	F.3 Non / partial disallowance of expenditure towards physicians samples	26-27
	F.4 Non disallowance of expenditure towards penalty by NPPA	27
	<i>Section B: Compliance Issues in Pharmaceuticals sector</i>	28-49
	F.5 Allocation of R&D / other common expenses	29-30
	F.6 Allowance of concessions/deduction/rebate/relief	31-32
	F.7 Setting off /carry forward of depreciation/business loss/ capital loss	32-34
	F.8 Allowance of business expenditure	34-35
	F.9 Allowance of R&D expenses	35-36
	F.10 Mistake in allowing expenses on which TDS was not deducted/deposited	37
	F.11 Inconsistency in assessment	38
	F.12 Arithmetical errors in computation of income and tax	39-40
	F.13 Assessment of Income under special provision	40-41
	F.14 Assessment of Income under normal provision	41-42
	F.15 Classification and computation of capital gains	42-43
	F.16 International transactions	43-44
	F.17 Other cases	44-47
G.	Abbreviations	51